CN1126073A - Compound cinrofloxacin ear drop - Google Patents
Compound cinrofloxacin ear drop Download PDFInfo
- Publication number
- CN1126073A CN1126073A CN 94113676 CN94113676A CN1126073A CN 1126073 A CN1126073 A CN 1126073A CN 94113676 CN94113676 CN 94113676 CN 94113676 A CN94113676 A CN 94113676A CN 1126073 A CN1126073 A CN 1126073A
- Authority
- CN
- China
- Prior art keywords
- compound
- cinrofloxacin
- ear drop
- formulation
- ciprofloxacin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The ear drops of compound ciproxacin for curing acute and chronic tympanitis, otitis externa and myringitis with quick and distinct curative effect and very low by-effect contain ciproxacin and its salts, glycocorticosteroid and its salts, metronidazole and its derivative, glycerin, alcohol and distilled water.
Description
The present invention relates to medicine field, is a kind of aural preparations that is used for the treatment of acute and chronic otitis media, otitis externa, myringitis.
Acute and chronic otitis media, otitis externa, myringitis are clinical otology commonly encountered diseases, especially chronic otitis media is one of persistent ailment of otology, pathogenic bacterium mostly are staphylococcus aureus, Hemolytic streptococcus, bacillus pyocyaneus, Bacillus proteus and escherichia coli, and the part chronic otitis media can be with mixed infections such as anaerobe.The ear drop main component that is used for the treatment of above-mentioned ear disease at present both at home and abroad clinically mostly is the phenol of chloromycetin, gentamycin, kanamycin, neomycin and the disinfection preservative class of antibiotic inflammation, boric acid etc.The former is because of for many years abuse, and its bacterial resistance phenomenon is very serious, and curative effect is lower, and all can enter the internal ear toxigenicity through the garden fenestrated membrane.Chloromycetin, neomycin and gentamycin also can cause vestibular deficiency, and the cochlea irreversible lesion is now gradually used less as aural preparations; The latter has certain curative effect, but acts on shallow table, and can suppress the cell normal function to some extent, how with in addition damage tympanum or mucosa, the clinical people of having advocate in treatment few with or need not.
It is the ear drop of main component with the ciprofloxacin that task of the present invention provides a kind of, has efficient sterilizing, antiinflammatory, convergence, analgesic effect.
It is main component that compound cinrofloxacin ear drop of the present invention is selected ciprofloxacin for use, is equipped with ancillary drug glucocorticoid and its esters, metronidazole and derivant thereof, glycerol, ethanol etc., and adding distil water is prepared from.
Its synthetic prescription is: ciprofloxacin and its esters 5-10g
Glucocorticoid and its esters 0.1-2g
Metronidazole and derivant 5-10g thereof
Ethanol 0-200ml
Glycerol 0-400ml
Distilled water adds to 1000ml
The present invention's main constituent of filling a prescription is ciprofloxacin and its esters.Ciprofloxacin is the up-to-date antibacterials the strongest with effect in the present third generation quinolones, has a broad antifungal spectrum, antibacterial activity is strong, gram negative bacteria and positive bacteria all there is stronger antibacterial action, particularly the effect to the gram negative bacteria that comprises bacillus pyocyaneus surpasses aminoglycosides antibiotics, untoward reaction is then less and light, different with antibiotic mechanism of action such as beta-lactam, aminoglycosides, thereby there is not the crossing drug resistant phenomenon with other antibiotic, to cephalosporin and the drug-fast bacterial strain of aminoglycosides, more than 90% to the ciprofloxacin sensitivity.
In prescription, can add glucocorticoid and its esters.Glucocorticoid and its esters have antiinflammatory, antianaphylactic effect, can reduce the permeability of capillary wall and cell membrane, alleviate body tissue to infringement pathological reaction that sexual stimulus produced, reduce inflammation and ooze out, and alleviate or the formation of Film with Preventing Adhesion.
In prescription, add metronidazole and derivant thereof, be applicable to the chronic otitis media patient of part with anaerobe mixed infection.
Adding glycerol in prescription can increase viscosity and lubricity, and can prolong drug effect.
In prescription, add permeability and the sterilizing power that ethanol can strengthen medicine, and forming in ear of middle ear also had facilitation.
This product is colourless or yellowish clear liquid, and PH4.5～5.0 are weakly acidic solution, help the auditory meatus surface skin and produce acid mantle with antibacterial action, and then control infection.Through the room temperature reserved sample observing, in above-mentioned PH scope, each ingredient stability is good in the preparation.Can adjust ingredient and content according to the different state of an illness, select for use ethanol or glycerol or the mixture of the two to make solvent and adjust its consumption.Clinical practice shows: obvious effective rate is 82.2%; Effective percentage is 95.5%; Average onset time (dried ear time) is 3-4 days.Evident in efficacy, easy to use, side effect is comparatively slight, is that the comparatively ideal medicine of acute and chronic otitis media is treated by a new generation at present.Implement the present invention and will produce important social benefit and economic benefit.
Embodiment 1:
Get ciprofloxacin 5g, metronidazole 10g is dissolved in the 700ml distilled water; Other gets hydrocortisone 0.5g and is dissolved in the 100ml ethanol, it is slowly added in the above-mentioned Ciloxan again, and the limit edged stirs, and adds glycerol 100ml, and mixing filters, and adds distilled water to 1000ml on filter, stirs promptly.
Embodiment 2:
Get ciprofloxacin 5g, metronidazole 5g, plug not loose sodium phosphate 0.1g in ground is dissolved in the 700ml distilled water, adds 200ml glycerol, and mixing filters, and adds distilled water to 1000ml on filter, stirs promptly.
Embodiment 3:
Extracting lactic acid ciprofloxacin 5g, metronidazole 5g is dissolved in the 700ml distilled water, other gets hydrocortisone acetate 1g and is dissolved in the 200ml ethanol, it is slowly added in the above-mentioned ciprofloxacin solution again, and the limit edged stirs, filter, on filter, add distilled water, stir promptly to 1000ml.
Claims (5)
1, compound cinrofloxacin ear drop is characterized in that being is main component with ciprofloxacin and its esters, can allocate the faintly acid liquid pharmaceutical formulation of ancillary drug into, and per thousand ml of formulation contain ciprofloxacin and its esters 5-10g.
2, compound cinrofloxacin ear drop according to claim 1 is characterized in that per thousand ml of formulation can add glucocorticoid and its esters of 0.1-2g.
3, compound cinrofloxacin ear drop according to claim 1 is characterized in that per thousand ml of formulation can add metronidazole and the derivant thereof of 5-10g.
4, compound cinrofloxacin ear drop according to claim 1 is characterized in that per thousand ml of formulation can add the 200ml ethanol of (containing 200ml).
5, compound cinrofloxacin ear drop according to claim 1 is characterized in that per thousand ml of formulation can add the 400ml glycerol of (containing 400ml).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 94113676 CN1126073A (en) | 1994-10-24 | 1994-10-24 | Compound cinrofloxacin ear drop |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 94113676 CN1126073A (en) | 1994-10-24 | 1994-10-24 | Compound cinrofloxacin ear drop |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1126073A true CN1126073A (en) | 1996-07-10 |
Family
ID=5036799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 94113676 Pending CN1126073A (en) | 1994-10-24 | 1994-10-24 | Compound cinrofloxacin ear drop |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1126073A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112494497A (en) * | 2020-12-22 | 2021-03-16 | 唐凌文 | Compound liquid preparation and preparation method and application thereof |
-
1994
- 1994-10-24 CN CN 94113676 patent/CN1126073A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112494497A (en) * | 2020-12-22 | 2021-03-16 | 唐凌文 | Compound liquid preparation and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2553363C2 (en) | Antiseptic compositions and applications thereof | |
| Parks et al. | Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of ulcerative keratitis | |
| CN103285028A (en) | Composite antibacterial agent of chitosan and organosilicone quaternary ammonium salt and preparation method of composite antibacterial agent | |
| EP0337328B1 (en) | Use of ofloxacin or a salt thereof for preparing a topical preparation for treating otopathy | |
| EP0964687B1 (en) | Pharmaceutical compositions with antimicrobial activity | |
| KR20150040972A (en) | Antibacterial composition for topical use | |
| US6017912A (en) | Topical fluoroquinolone antibiotics in an alcohol and acetone vehicle | |
| WO2008104076A1 (en) | Electrocolloidal silver and echinacea root antimicrobial formulation | |
| Ahmed et al. | Antimicrobial activity of glycerine‐ichthammol in otitis externa | |
| US20040126414A1 (en) | Methods and compositions for treating and preventing ear infections | |
| CN109966410B (en) | Antibacterial composition and wound dressing containing same | |
| CN1126073A (en) | Compound cinrofloxacin ear drop | |
| CN104224802B (en) | A kind of moxifloxacin hydrochloride auristilla and preparation method thereof | |
| AU2007298511B2 (en) | Compositions for prevention and treatment of mastitis and metritis | |
| Torres et al. | Therapeutic efficacy of the combination of aztreonam with cefotaxime in the treatment of severe nosocomial pneumonia | |
| RU2512757C1 (en) | Antibacterial and regenerative agent presented in form of topical oily gel | |
| Liedl | Katheterassoziierte Harnwegsinfektionen | |
| ES2273872T3 (en) | GATIFLOXACINO AS INHIBITOR OF THE PRODUCTION OF CYTOKINES. | |
| CN115487226B (en) | External natural bactericide pharmaceutical composition | |
| Amalia et al. | Effectiveness of Piper betle leaf infusion as a palpebral skin antiseptic | |
| CN117244009A (en) | Novel auditory canal antibacterial gel | |
| TWI687229B (en) | Biomaterial Having a Synergistic Effect, and Method for Manufacturing the Same | |
| Slattery et al. | Otic preparations | |
| CN107519145B (en) | Tosufloxacin tosylate effervescent tablet for children and preparation method thereof | |
| US20080248135A1 (en) | Combination Therapy for Otitis with Antiseptic and pH Adjustment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |